SMN1 and proximal spinal muscular atrophy: For example, nusinersen (shown in Figure 1) is a splice-switching oligonucleotideapproved for the treatment of spinal muscular atrophy (SMA), a geneticdisorder caused by mutations to the SMN1 gene and inefficient productionof survival motor neuron (SMN) protein.